News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tobira Therapeutics Inc. Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults


7/19/2011 9:12:22 AM

MANALAPAN, N.J.--(BUSINESS WIRE)--Tobira Therapeutics, a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV infection, announced the results of a Phase l, open-label, cross-over study that explored the pharmacokinetics (PK), safety and tolerability of cenicriviroc (CVC) and tenofovir disoproxil fumarate (TDF) when coadministered in healthy adults. The study findings were presented today at the 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Rome, Italy.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES